Mitosis-targeting therapies: A troubleshooting guide

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 519-528

  Doménech, Elena ^a   Malumbres, Marcos ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; AMG 900; ANTINEOPLASTIC AGENT; ARQ 621; ARRY 520; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; AZD 4877; BARASERTIB; CBB 2001; CYCLIN DEPENDENT KINASE 1; GSK 461364; GSK 923295; ISPINESIB; KINESIN; LITRONESIB; MK 0731; MPI 0479605; N (3 AMINOPROPYL) N [1 (3 BENZYL 7 CHLORO 4 OXO 4H CHROMEN 2 YL) 2 METHYLPROPYL] 4 METHYLBENZAMIDE; NMS P715; ON 01910NA; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; REVERSINE; RIGOSERTIB; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLASERTIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; MITOSIS; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NAUSEA; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA;

EID: 84885954101     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.011     Document Type: Review

References (102)

1. Malumbres M: Cell cycle-based therapies move forward. Cancer Cell 2012, 22:419-420.
2. Toledo LI, Murga M, Fernandez-Capetillo O: Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 2011, 5:368-373.
3. Bucher N, Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008, 98:523-528. (Pubitemid 351214533)
4. Manchado E, Guillamot M, Malumbres M: Killing cells by targeting mitosis. Cell Death Differ 2012, 19:369-377.
5. Komlodi-Pasztor E, Sackett DL, Fojo AT: Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012, 18:51-63.
6. Mitchison TJ: The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012, 23:1-6.
7. Malumbres M: Physiological relevance of cell cycle kinases. Physiol Rev 2011, 91:973-1007.
8. Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166.
9. Malumbres M, Pevarello P, Barbacid M, Bischoff JR: CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008, 29:16-21.
10. Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010, 10:825-841.
11. Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci- Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T et al.: Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2011, 2:395.
12. Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G: A phase I, doseescalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012, 48:179-186.
13. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL: Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 2012, 36:98-103.
14. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J et al.: A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012, 23:1307-1313.
15. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosello S, Andreu J, Jung J, Sanchis- Garcia JM et al.: Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012, 18:4764-4774.
16. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR: Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012, 18:4775-4784.
17. Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X et al.: Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or - refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012, 127:63-69.
18. Mosse YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH, Blaney SM: Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res 2012, 18:6058-6064.
19. Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI: Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2013, 31:370-380.
20. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U et al.: Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010, 70:10255-10264.
21. Tardif KD, Rogers A, Cassiano J, Roth BL, Cimbora DM, McKinnon R, Peterson A, Douce TB, Robinson R, Dorweiler I et al.: Characterization of the cellular and antitumor effects of MPI- 0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 2011, 10:2267-2275.
22. Jemaa M, Galluzzi L, Kepp O, Boileve A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A et al.: Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 2012, 11:2149-2158.
23. Rath O, Kozielski F: Kinesins and cancer. Nat Rev Cancer 2012, 12:527-539.
24. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G et al.: Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 2012, 30:1107-1115.
25. Esaki T, Seto T, Ariyama H, Arita S, Fujimoto C, Tsukasa K, Kometani T, Nosaki K, Hirai F, Yagawa K: Phase I study to assess the safety, tolerability and pharmacokinetics of AZD4877 in Japanese patients with solid tumors. Arch Drug Inf 2011, 4:23-31.
26. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD: First-time-inhuman study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 2012, 69: 733-741.
27. Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Muller-Mattheis V, Grimm MO et al.: Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 2013 http://dx.doi.org/10.1007/s10637-013-9926-y.
28. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A et al.: A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 69:165-172.
29. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM et al.: A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 2011, 67:447-454.
30. Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E et al.: A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs 2012, 30: 1088-1095.
31. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K et al.: A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 2012, 118:3556-3564.
32. Cortes J, Vidal M: Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 2012, 133:821-830.
33. Tyagi S, Bhui K, Singh R, Singh M, Raisuddin S, Shukla Y: Pololike kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73alpha in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol 2010, 80:1326-1334.
34. Maire V, Nemati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G et al.: Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res 2013, 73:813-823.
35. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E: Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008, 27:3244-3255. (Pubitemid 351733390)
36. Zhang L, Zhang S: ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res 2011, 37:591-600.
37. Ma Y, Weimer J, Fredrik R, Adam-Klages S, Sebens S, Caliebe A, Hilpert F, Eckmann-Scholz C, Arnold N, Schem C: Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. Arch Gynecol Obstet 2013 http://dx.doi.org/10.1007/ s00404-013-2719-x.
38. Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W: The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer 2013, 119: 904-914.
39. Janssen A, Kops GJ, Medema RH: Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 2009, 106:19108-19113.
40. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo AT: Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011, 8:244-250.
41. Archambault V, Glover DM: Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009, 10:265-275.
42. Nurse P: A long twentieth century of the cell cycle and beyond. Cell 2000, 100:71-78. (Pubitemid 30046296)
43. Fernandez-Miranda G, Trakala M, Martin J, Escobar B, Gonzalez A, Ghyselinck NB, Ortega S, Canamero M, Perez de Castro I, Malumbres M: Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development. Development 2011, 138:2661-2672.
44. de Carcer G, Manning G, Malumbres M: From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011, 10:2255-2262.
45. Fry AM, O'Regan L, Sabir SR, Bayliss R: Cell cycle regulation by the NEK family of protein kinases. J Cell Sci 2012, 125:4423-4433.
46. Glover DM: The overlooked greatwall: a new perspective on mitotic control. Open Biol 2012, 2:120023.
47. Higgins JM: Haspin: a newly discovered regulator of mitotic chromosome behavior. Chromosoma 2010, 119:137-147.
48. Perez de Castro I, de Carcer G, Malumbres M: A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28:899-912. (Pubitemid 47072171)
49. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD et al.: Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011, 17:875-882.
50. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM: Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007, 13:820-827. (Pubitemid 47038193)
51. Radomska HS, Alberich-Jorda M, Will B, Gonzalez D, Delwel R, Tenen DG: Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest 2012, 122:2955-2966.
52. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X et al.: Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012, 150:575-589.
53. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y: Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005, 65:2698-2704. (Pubitemid 40490070)
54. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
55. Liu-Sullivan N, Zhang J, Bakleh A, Marchica J, Li J, Siolas D, Laquerre S, Degenhardt YY, Wooster R, Chang K et al.: Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1). Oncotarget 2011, 2:1254-1264.
56. Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, Zhao Y, Mousses S, Yin HH, Von Hoff DD, Han H: Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol 2012, 83:452-461.
57. Huang HC, Shi J, Orth JD, Mitchison TJ: Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009, 16:347-358.
58. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I, Moreno S, Yamano H, Canamero M, Malumbres M: Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/ B55alpha,delta phosphatase. Cancer Cell 2010, 18:641-654.
59. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, Hathaway N, Dimova N, Cuny GD, King RW: Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpointdependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010, 18:382-395.
60. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S et al.: Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells 2012, 30:1064-1075.
61. Wagenblast J, Hirth D, Thron L, Arnoldner C, Diensthuber M, Stover T, Hambek M: Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck. Oncol Lett 2012, 4:175-177.
62. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G: Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008, 26:5511-5517.
63. Hofheinz RD, Al-Batran SE, Hochhaus A, Jager E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G: An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010, 16:4666-4674.
64. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP et al.: Distinct concentration-dependent effects of the pololike kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009, 69:6969-6977.
65. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ et al.: Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011, 17:3420-3430.
66. Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang Z et al.: Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001. Lab Invest 2012, 92:1503-1514.
67. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV et al.: Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 2009, 28:610-618.
68. Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS et al.: Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012, 36:982-989.
69. Diaz RJ, Golbourn B, Shekarforoush M, Smith CA, Rutka JT: Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol 2012, 108:349-360.
70. Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K et al.: A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res 2011, 35:1384-1389.
71. Dennis M, Davies M, Oliver S, D'Souza R, Pike L, Stockman P: Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol 2012, 70:461-469.
72. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P et al.: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011, 118: 6030-6036.
73. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M et al.: Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 67:945-954.
74. Dewerth A, Wonner T, Lieber J, Ellerkamp V, Warmann SW, Fuchs J, Armeanu-Ebinger S: In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma. Pediatr Surg Int 2012, 28:579-589.
75. de Paula Careta F, Gobessi S, Panepucci RA, Bojnik E, Morato de Oliveira F, Mazza Matos D, Falcao RP, Laurenti L, Zago MA, Efremov DG: The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica 2012, 97:1246-1254.
76. Chowdhury A, Chowdhury S, Tsai MY: A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma 2012, 53:462-471.
77. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL et al.: Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010, 70:9846-9854.
78. Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R et al.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett 2012, 22:4377-4385.
79. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA et al.: Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 2012, 58:916-923.
80. Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM, Schwartz GK: A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs 2013, 31:355-362.
81. Burris HA, 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P: A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011, 29:467-472.
82. Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC: A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010, 55:1323-1328.
83. Gomez HL, Philco M, Pimentel P, Kiyan M, Monsalvo ML, Conlan MG, Saikali KG, Chen MM, Seroogy JJ, Wolff AA et al.: Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Anticancer Drugs 2012, 23:335-341.
84. Good JA, Wang F, Rath O, Kaan HY, Talapatra SK, Podgorski D, Mackay SP, Kozielski F: Optimized S-trityl-L-cysteine based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J Med Chem 2013, 56:1878-1893.
85. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M: Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 2009, 23:1755-1762.
86. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med 2009, 7:63.
87. Woessner R, Tunquist B, Lemieux C, Chlipala E, Jackinsky S, Dewolf W Jr, Voegtli W, Cox A, Rana S, Lee P et al.: ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxaneresistant tumor models. Anticancer Res 2009, 29:4373-4380.
88. Tunquist BJ, Woessner RD, Walker DH: Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY- 520. Mol Cancer Ther 2010, 9:2046-2056.
89. Cox CD, Garbaccio RM: Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxanerefractory cancer: MK-0731 and analogs. Anticancer Agents Med Chem 2010, 10:697-712.
90. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR: Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011, 71:1385-1395.
91. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA et al.: Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3- kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012, 18:2048-2055.
92. Leinung M, Hirth D, Tahtali A, Diensthuber M, Stover T, Wagenblast J: Fighting cancer from different signalling pathways: effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN. Oncol Lett 2012, 4:1305-1308.
93. Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, Deutsch E: Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007, 97:1664-1672. (Pubitemid 350249356)
94. Niermann KJ, Moretti L, Giacalone NJ, Sun Y, Schleicher SM, Kopsombut P, Mitchell LR, Kim KW, Lu B: Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res 2011, 175:444-451.
95. Zhou N, Singh K, Mir MC, Parker Y, Lindner DJ, Dreicer R, Ecsedy JA, Teh BT, Zhang Z, Almasan A et al.: The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell cycle progression in bladder cancer cells in vitro and in vivo. Clin Cancer Res 2013, 19:1717-1728.
96. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N: Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009, 8:1921-1929.
97. Yoshida K, Nagai T, Ohmine K, Uesawa M, Sripayap P, Ishida Y, Ozawa K: Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukema cells. Biochem Pharmacol 2011, 82:1884-1890.
98. Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI: Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Br J Cancer 2012, 107:1692-1701.
99. Jeet V, Russell PJ, Verma ND, Khatri A: Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets 2012, 12:144-163.
100. Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN: Cotreatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat 2012, 135:433-444.
101. Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL: Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 2013, 31:39-45.
102. Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK et al.: Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res 2012, 18: 4633-4645.